Fulgent Genetics Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Fulgent Genetics ha aumentado sus ingresos a un ritmo medio anual de 24.3%, mientras que la industria Healthcare ha visto aumentar sus ingresos growing a 9% anualmente. Los ingresos han crecido growing a un ritmo medio anual de 37.5%.
Información clave
8.8%
Tasa de crecimiento de los beneficios
7.7%
Tasa de crecimiento del BPA
| Crecimiento de la industria Healthcare | 8.5% |
| Tasa de crecimiento de los ingresos | 29.5% |
| Rentabilidad financiera | -15.5% |
| Margen neto | -58.0% |
| Próxima actualización de resultados | 03 May 2024 |
Actualizaciones de resultados anteriores recientes
Recent updates
Are Investors Undervaluing Fulgent Genetics, Inc. (NASDAQ:FLGT) By 32%?
Mar 01
Fulgent Genetics: Buy Growth Ahead Below Liquidation Value
Feb 21Subdued Growth No Barrier To Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Price
Jan 17Is Fulgent Genetics (NASDAQ:FLGT) Using Debt Sensibly?
Dec 14Fulgent Genetics (NASDAQ:FLGT) Has Debt But No Earnings; Should You Worry?
Aug 09Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report
May 09Fulgent Genetics (NASDAQ:FLGT) Is Looking To Continue Growing Its Returns On Capital
Apr 19Why We Like The Returns At Fulgent Genetics (NASDAQ:FLGT)
Jan 15Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?
Dec 28What Does The Future Hold For Fulgent Genetics, Inc. (NASDAQ:FLGT)? These Analysts Have Been Cutting Their Estimates
Nov 16Why Fulgent Genetics, Inc. (NASDAQ:FLGT) Could Be Worth Watching
Oct 27Wait For Fulgent Genetics To Grow Up
Oct 13We Like Fulgent Genetics' (NASDAQ:FLGT) Returns And Here's How They're Trending
Sep 19Fulgent Genetics (NASDAQ:FLGT) Seems To Use Debt Rather Sparingly
Sep 05Fulgent Genetics: Poised To Survive Its Post-Covid Hangover
Jul 26Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Low P/E No Reason For Excitement
Jul 21Fulgent Genetics (NASDAQ:FLGT) Is Investing Its Capital With Increasing Efficiency
Jun 04Fulgent Is Putting Its Cash Bonanza To Work
May 15These 4 Measures Indicate That Fulgent Genetics (NASDAQ:FLGT) Is Using Debt Safely
May 04Fulgent Genetics: Now The Going Could Get Much Tougher
Apr 10Fulgent Genetics: COVID Bolstered The Underlying Business
Mar 17Fulgent Genetics: Somewhat Disappoints With A Marked Slowdown In Its NGS Business
Feb 27Fulgent Genetics Stock: 35% Off Its Recent Highs - It Is Now A Buy
Feb 09Fulgent Genetics: Sell Volatility
Jan 26Fulgent Genetics (NASDAQ:FLGT) Has A Rock Solid Balance Sheet
Jan 25Fulgent Genetics: Improving Outlook, But Shares Aren't Quite A Buy
Jan 09Fulgent Genetics: Undervalued, High Growth, And A COVID Hedge To Boot
Dec 20I Ran A Stock Scan For Earnings Growth And Fulgent Genetics (NASDAQ:FLGT) Passed With Ease
Dec 14Fulgent: Now Cheap Enough
Dec 06Desglose de ingresos y gastosBeta
Cómo gana y gasta dinero Fulgent Genetics. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Dec 23 | 289 | -168 | 128 | 41 |
| 30 Sep 23 | 286 | -64 | 113 | 38 |
| 30 Jun 23 | 307 | -49 | 132 | 35 |
| 31 Mar 23 | 365 | -26 | 139 | 33 |
| 31 Dec 22 | 619 | 143 | 144 | 29 |
| 30 Sep 22 | 803 | 272 | 141 | 28 |
| 30 Jun 22 | 925 | 392 | 118 | 26 |
| 31 Mar 22 | 953 | 461 | 96 | 25 |
| 31 Dec 21 | 993 | 507 | 75 | 24 |
| 30 Sep 21 | 1,036 | 569 | 58 | 21 |
| 30 Jun 21 | 910 | 493 | 48 | 18 |
| 31 Mar 21 | 773 | 417 | 40 | 15 |
| 31 Dec 20 | 422 | 214 | 30 | 12 |
| 30 Sep 20 | 135 | 48 | 21 | 9 |
| 30 Jun 20 | 44 | 3 | 15 | 7 |
| 31 Mar 20 | 35 | 0 | 13 | 7 |
| 31 Dec 19 | 33 | 0 | 12 | 7 |
| 30 Sep 19 | 30 | -2 | 11 | 6 |
| 30 Jun 19 | 25 | -4 | 11 | 6 |
| 31 Mar 19 | 22 | -6 | 10 | 6 |
| 31 Dec 18 | 21 | -6 | 10 | 6 |
| 30 Sep 18 | 20 | -5 | 10 | 5 |
| 30 Jun 18 | 19 | -6 | 10 | 5 |
| 31 Mar 18 | 18 | -5 | 10 | 5 |
| 31 Dec 17 | 19 | -3 | 9 | 4 |
| 30 Sep 17 | 20 | 0 | 9 | 4 |
| 30 Jun 17 | 21 | -5 | 8 | 4 |
| 31 Mar 17 | 20 | -13 | 7 | 4 |
| 31 Dec 16 | 18 | -14 | 7 | 4 |
| 30 Sep 16 | 15 | -22 | 9 | 6 |
| 30 Jun 16 | 13 | -15 | 7 | 5 |
| 31 Mar 16 | 11 | -6 | 7 | 5 |
| 31 Dec 15 | 10 | -5 | 5 | 4 |
| 31 Dec 14 | 1 | -1 | 1 | 1 |
Ingresos de calidad: FLGT actualmente no es rentable.
Margen de beneficios creciente: FLGT actualmente no es rentable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: FLGT no es rentable, pero ha reducido pérdidas en los últimos 5 años a un ritmo de 24.3% al año.
Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de FLGT en el último año con su media de 5 años, ya que actualmente no es rentable.
Beneficios vs. Industria: FLGT no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el del sector Healthcare (0.3%).
Rentabilidad financiera
Alto ROE: FLGT tiene un Rendimiento de los fondos propios negativo (-5.15%), ya que actualmente no es rentable.